ReviewThe Journal of experimental medicine2020
Interleukin-17 cytokines: Effectors and targets in psoriasis-A breakthrough in understanding and treatment.
Review in The Journal of experimental medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 88 citations in OpenAlex.
- Altered subgenual anterior cingulate cortex connectivity in psoriasis patients with depression: a resting-state fMRI case-control study.Annals of general psychiatry · 2026Article
- A Multi-Omics Study of Comorbid Mechanisms Between Depression and Inflammatory Dermatoses Identifies FADS1 and TMEM258 as Therapeutic Targets.Clinical, cosmetic and investigational dermatology · 2026Article
- Assessment of Serum and Saliva CRP, IL-17, and IL-19 Levels in Patients with Different Severity of Acne Vulgaris.International journal of molecular sciences · 2025Article
- CRISPR/Cas9-Mediated Knockout and Overexpression Studies Unveil the Role of PD-L1 in Immune Modulation in a Psoriasis-like Mouse Model.Inflammation · 2025Article
- Metabolic reprogramming of interleukin-17-producing γδ T cells promotes ACC1-mediated de novo lipogenesis under psoriatic conditions.Nature metabolism · 2025Article
- Topical delivery of pterostilbene nanoemulgel ameliorates imiquimod-induced psoriasis-like skin inflammation in mice.Nanomedicine (London, England) · 2025Article
- Targeting Cytokine Dysregulation in Psoriasis: The Role of Dietary Interventions in Modulating the Immune Response.International journal of molecular sciences · 2025Review
- Causal associations between psoriasis and atopic dermatitis: A bidirectional Mendelian randomization study.PloS one · 2025Article
- MrgprA3 neurons drive cutaneous immunity against helminths through selective control of myeloid-derived IL-33.Nature immunology · 2024Article
- Skin hepcidin initiates psoriasiform skin inflammation via Fe-driven hyperproliferation and neutrophil recruitment.Nature communications · 2024Article
- Psoriasis as a Systemic Disease.Deutsches Arzteblatt international · 2024Review
- Association between allergic diseases and both psoriasis and psoriatic arthritis: a bidirectional 2-sample Mendelian randomization study.Archives of dermatological research · 2024Article
- Role of autoreactive Tc17 cells in the pathogenesis of experimental autoimmune encephalomyelitis.Neuroprotection (Chichester, England) · 2024Article
- Efficacy and Safety of Topical Tacrolimus Microemulsion Applied Twice Daily in Patients with Mild to Moderate Scalp Psoriasis.Dermatology and therapy · 2024Article
- Attenuated effects of topical vinpocetine in an imiquimod-induced mouse model of psoriasis.Journal of Taibah University Medical Sciences · 2024Article
- Role of Interleukin-17 family cytokines in disease severity of patients with knee osteoarthritis.Advances in rheumatology (London, England) · 2024Article
- CYSLTR1 antagonist inhibits Th17 cell differentiation by regulating the NF-κB signaling for the treatment of psoriasis.International journal of biological sciences · 2024Article
- Cytokine Modulators in Plaque Psoriasis - A Review of Current and Prospective Biologic Therapeutic Approaches.JAAD international · 2022Review
- Mupirocin blocks imiquimod-induced psoriasis-like skin lesion by inhibiting epidermal isoleucyl-tRNA synthetase.Cell communication and signaling : CCS · 2022Article
- Discovery and multi-parametric optimization of a high-affinity antibody against interleukin-25 with neutralizing activity in a mouse model of skin inflammation.Antibody therapeutics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The IL-17 cytokine family comprising IL-17A to IL-17F and receptor subunits IL-17RA to IL-17RE represents a genetically ancient intercellular network regulating local tissue homeostasis. Its pivotal role in antifungal defense and its central position in the pathogenesis of inflammatory diseases including psoriasis were discovered only relatively late in the early 2000s. Since the connection of dysregulated IL-17 and psoriasis pathogenesis turned out to be particularly evident, a number of monoclonal antibodies targeting IL-17 pathways have been approved and are used as first line treatment of moderate-to-severe plaque psoriasis and psoriatic arthritis, and further agents are currently in clinical development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.